Phase Ib Study of AlpeliSib with PEmbroLizumab in Patients with MEtastatic Breast CaNcer or MelanomA (SELENA)
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Alpelisib (Primary) ; Pembrolizumab (Primary)
- Indications Breast cancer; Malignant melanoma; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms SELENA
Most Recent Events
- 29 Jan 2025 Status changed from not yet recruiting to recruiting.
- 13 Aug 2024 New trial record